Evaluation of Calgranulin B in Stools from the Patients with Colorectal Cancer
Authors:
- Young-Kyoung ShinYSYoung-Kyoung Shin
- Seok-Byung LimSLSeok-Byung Lim
- Sung-Hye HongSHSung-Hye Hong
- Seung-Yong JeongSJSeung-Yong Jeong
- Jae-Gahb ParkJPJae-Gahb Park
- 1 November 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 51 (11) , 1703-1709
Abstract
Calprotectin (heterodimer of calgranulin A and B) has been previously studied as a candidate stool marker for detecting colorectal cancer. We assessed the clinical usefulness of calgranulin B as a stool marker for colorectal cancer in a pilot study of patients with colorectal cancer. We performed 2-DE-based proteomics to screen stool markers for colorectal cancer. We checked the calgranulin B in stools from 77 colorectal cancer patients and from 75 controls by western blot and enzyme-linked immunosorbent assay. We measured calgranulin A using the same methods, and stool hemoglobin by immunologic fecal occult blood test. Fecal calgranulin A did not show any difference, but stool calgranulin B of colorectal cancer patients was significantly higher than controls [50.6 ng/mg stool protein (SD, 34.8) vs. 20.2 ng/mg stool protein (SD,24.0), respectively, P < 0.001). At the cut off level 24.4 ng/mg stool protein, the sensitivity was somewhat higher than fecal occult blood test (72.0 percent vs. 62.3 percent) but the specificity was much lower than fecal occult blood test (77.1 percent vs. 98.7 percent). Calgranulin B was increased in stools of colorectal cancer patients but our results suggest that colorectal cancer screening by determination of stool calgranulin B would not be better than conventional fecal occult blood test.Keywords
This publication has 24 references indexed in Scilit:
- Colorectal Inflammation is Well Predicted by Fecal Calprotectin in Children with Gastrointestinal SymptomsJournal of Pediatric Gastroenterology and Nutrition, 2005
- Colorectal cancer screening: prospects for molecular stool analysisNature Reviews Cancer, 2005
- Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT)Gut, 2004
- Faecal calprotectin levels and colorectal neoplasiaGut, 2001
- Colorectal cancer screening in the UK: Joint Position Statement by the British Society of Gastroenterology, the Royal College of Physicians, and the Association of Coloproctology of Great Britain and IrelandGut, 2000
- Faecal calprotectin levels in a high risk population for colorectal neoplasiaGut, 2000
- Faecal Calprotectin: A Novel Test for the Diagnosis of Colorectal Cancer?Scandinavian Journal of Gastroenterology, 1993
- Assessment of the Neutrophil Dominating Protein Calprotectin in Feces: A Methodologic StudyScandinavian Journal of Gastroenterology, 1992
- A genetic model for colorectal tumorigenesisCell, 1990
- ELISA FOR OCCULT FAECAL ALBUMINThe Lancet, 1987